Business Context and Reporting Period
This Form 6-K filing by Cellyan Biotechnology Co., Ltd (formerly Hong Kong Pharma Digital Technology Holdings Limited) covers the month of December 2025. The report details corporate actions approved at the Annual General Meeting held on December 12, 2025, including a formal name change and amendments to the company's capital structure and governing documents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and structural changes rather than financial performance.
Material Changes
- Name Change: The company's English name was changed from "Hong Kong Pharma Digital Technology Holdings Limited" to "Cellyan Biotechnology Co., Ltd". A new dual foreign Chinese name was also adopted.
- Authorized Share Capital Increase: Authorized share capital increased from US$100,000 (100,000,000 shares) to US$1,000,000 (1,000,000,000 shares).
- Share Class Restructuring: The authorized capital was amended to comprise 940,000,000 Class A ordinary shares and 60,000,000 Class B ordinary shares, all with a par value of US$0.001.
- Governing Documents: The Fourth Amended and Restated Memorandum and Articles of Association were approved and adopted.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, specific risk factors, or contingencies. The document serves as a notification of the legal implementation of the shareholder-approved resolutions.
Investor Verification Checklist
- Verify the effective date of the name change via the Certificate of Incorporation on Change of Name (Exhibit 1.1).
- Confirm the new share class structure (940M Class A / 60M Class B) in the updated Memorandum and Articles of Association (Exhibit 1.2).
- Monitor future filings for the first financial report under the new corporate identity.